Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGY: M281 in Adults with Warm Autoimmune Hemolytic Anemia
jRCT2071220079Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial of nipocalimab in warm autoimmune hemolytic anemia (wAIHA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Achieving Durable Response of Improvement in Hemoglobin (Hgb). Started Jun 2023; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on jRCT2071220079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220079.